472 results
6-K
EX-99.3
SNY
Sanofi
28 May 24
Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
12:04pm
of observation in an emergency department or urgent care facility; or resulting in death. Key secondary endpoints included change from baseline in lung function … to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S
F-3ASR
EX-25.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
Reserve Bank (2nd District)
New York, NY
Federal Deposit Insurance Corporation
Washington, D.C.
New York State Banking Department
Albany, NY
Whether
F-3ASR
EX-1.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
a target of any economic sanctions (i) which are (x) administered by the Office of Foreign Assets Control of the U.S. Department of Treasury (“OFAC
F-3ASR
EX-4.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
200, Jacksonville, FL 32256, Attn: Transfer Department and (ii) for all other purposes, at the address of the Trustee specified in Section 105
6-K
EX-99.1
SNY
Sanofi
20 Mar 24
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
2:07pm
of Department of Dermatology and Allergy, University Hospital Schleswig-Holstein
“Despite available treatment options, not all patients with moderate
6-K
EX-99.3
hzme ewgeh
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.2
blggqogbzt6tdj c8m1
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.1
eqmba aj7gm
1 Dec 23
Current report (foreign)
12:19pm
6-K
EX-99.1
ypm3n
20 Oct 23
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2:31pm
6-K
EX-99.1
xww0xiqx
10 Aug 23
Recommendation for use in all infants below 8 months of age follows earlier than anticipated FDA approval and unanimous FDA Advisory Committee vote
9:50am
6-K
EX-99.1
3m3q6 wdz
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
11-K
0uhstvwqsu76xau6w6
28 Jun 23
Annual report of employee stock purchases
2:32pm
11-K
809umsf
28 Jun 23
Annual report of employee stock purchases
2:31pm
6-K
EX-99.2
gcmyeb9 9eju
23 May 23
Current report (foreign)
1:01pm
SC TO-T/A
EX-99
lwn7zuk1tixkb2matjpp
26 Apr 23
Third party tender offer statement (amended)
6:16am
SC TO-T/A
EX-99
ublw87454sdo56thshkw
10 Apr 23
Third party tender offer statement (amended)
4:38pm
6-K
EX-99.1
gcefvammn8rwlov8hwf
21 Nov 22
European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease
10:05am
6-K
EX-99.1
28v9si5bo6ubc
15 Nov 22
Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission
3:01pm
6-K
EX-99.1
lby1crovyr7lybb
12 Sep 22
Evolution of the Board of Directors
7:07am
11-K
nlqvaayykiypwobskv
29 Jun 22
Annual report of employee stock purchases
11:48am